| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is fungal cytochrome P450 14α-sterol demethylase (CYP51/ERG11); voriconazole camphorsulfonate binds the heme iron of CYP51 and inhibits lanosterol demethylation, depleting ergosterol and causing accumulation of toxic sterol intermediates, leading to fungal cell membrane disruption and growth inhibition.
|
|---|---|
| ln Vitro |
Voriconazole camphorsulfonate exhibits significant activity against both Apiospermum and C. neoformans, with MICs of 0.5 μg/mL and 0.125-0.25 μg/mL respectively [1]. Fungal growth is inhibited and cell membranes are damaged when voriconazole camphorsulfonate inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase [2].
Voriconazole camphorsulfonate inhibits CYP51 and shows broad-spectrum antifungal activity against Aspergillus, Candida, and other fungi; its activity is assessed by broth microdilution MIC testing against clinical isolates, with potent activity against moulds and yeasts, and it is a second-generation triazole with enhanced potency compared with fluconazole. |
| ln Vivo |
In a dose-dependent way, voriconazole (5–20 mg/kg; orally for 21 days) camphorsulfonate prolongs survival. In the lungs, voriconazole (40 mg/kg/day) camphorsulfonate lowers the fungal burden [3].
In vivo, voriconazole camphorsulfonate is effective in animal models of invasive aspergillosis, candidemia, and other fungal infections, with tissue penetration into the central nervous system and lung; it is clinically used for invasive aspergillosis, esophageal candidiasis, and candidemia, with efficacy correlated with plasma trough concentrations and CYP2C19 genotype. |
| Enzyme Assay |
Fungal CYP51 activity is measured by incubating microsomal fractions from Candida or Aspergillus with lanosterol or a fluorogenic substrate in the presence of NADPH and graded voriconazole camphorsulfonate concentrations; ergosterol depletion and sterol intermediate accumulation are quantified by HPLC or LC-MS/MS, and IC50 values are calculated.
|
| Cell Assay |
Fungal cells (Candida albicans, Aspergillus fumigatus) are treated with voriconazole camphorsulfonate (0.01–16 µg/mL) in RPMI medium, and growth inhibition is measured by broth microdilution MIC assays; ergosterol content is quantified by HPLC, membrane integrity by fluorescent probes, and cell viability by metabolic assays.
|
| Animal Protocol |
Animal/Disease Models: Male specific pathogen-free BALB/cByJ mice [3]
Doses: 1, 5, 20 mg/kg/day Route of Administration: Orally one time/day for 21 days Experimental Results: Improved survival in a dose-response manner, median Survival rates were 21, 28, and 35 days (MST) at doses of 1, 5, and 20 mg/kg, respectively. Mice or rats with invasive aspergillosis or candidemia receive voriconazole camphorsulfonate by oral or intravenous administration at doses selected from pharmacokinetic studies; tissue fungal burden is measured by quantitative culture or qPCR, survival is monitored, and plasma and tissue drug concentrations are measured by HPLC or LC-MS/MS to establish pharmacokinetic–pharmacodynamic relationships. |
| References |
|
| Molecular Formula |
C16H14F3N5O
|
|---|---|
| Molecular Weight |
581.61
|
| Exact Mass |
581.191
|
| CAS # |
137234-71-0
|
| Related CAS # |
Voriconazole;137234-62-9
|
| PubChem CID |
86626424
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.527
|
| tPSA |
156.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
40
|
| Complexity |
852
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O.CC1(C)[C@H]2CC[C@]1(CS(=O)(=O)O)C(=O)C2
|
| InChi Key |
AMYMCJHOGKVJHB-YAXAZOLQSA-N
|
| InChi Code |
InChI=1S/C16H14F3N5O.C10H16O4S/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,7-10,25H,6H2,1H3;7H,3-6H2,1-2H3,(H,12,13,14)/t10-,16+;7?,10-/m00/s1
|
| Chemical Name |
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol;[(1R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7194 mL | 8.5968 mL | 17.1937 mL | |
| 5 mM | 0.3439 mL | 1.7194 mL | 3.4387 mL | |
| 10 mM | 0.1719 mL | 0.8597 mL | 1.7194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.